Evidence map›Paper›PMID 41509280›Full record

ArticlebioRxiv : the preprint server for biology2026

TMEM33 deletion potentiates anti-tumor CD8

Matthew T Jackson, Tianming Zhao, Gusztav Milotay, Isabela Pedroza-Pacheco, Yanshu Cai, Claire Willis, Su M Phyu, Bruno Beernaert, Jamie Tw Kwon, Hala Estephan and 15 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Matthew T JacksonDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0003-4916-3719
Tianming ZhaoDepartment of Oncology, University of Oxford, Oxford, UK.
Gusztav MilotayDepartment of Oncology, University of Oxford, Oxford, UK.
Isabela Pedroza-PachecoCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Yanshu CaiCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Claire WillisCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Su M PhyuDepartment of Oncology, University of Oxford, Oxford, UK.
Bruno BeernaertDepartment of Oncology, University of Oxford, Oxford, UK.
Jamie Tw KwonDepartment of Oncology, University of Oxford, Oxford, UK.
Hala EstephanDepartment of Oncology, University of Oxford, Oxford, UK.
Vinnycius Pereira AlmeidaLudwig Institute for Cancer Research, University of Oxford, UK.
Maria AggelakopoulouCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Silvia PanettiLudwig Institute for Cancer Research, University of Oxford, UK.
Christian ZierhutThe Institute of Cancer Research, London, UK.
Tim ElliottCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Eleni AdamopoulouCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jan RehwinkelMRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Malcolm Jw SimCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Amit GroverImmuno-Oncology, Circuits-Engagers & Cell Therapy, Oncology R&D, AstraZeneca, Cambridge, UK.
Dmitry I GabrilovichImmuno-Oncology, Circuits-Engagers & Cell Therapy, Oncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Benjamin P FairfaxDepartment of Oncology, University of Oxford, Oxford, UK.
Eric HonoréUniversité Côte d'Azur, Centre National de la Recherche Scientifique, Institut national de la santé et de la recherche médicale, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France.
David R WithersCentre for Immuno-Oncology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
John C ChristiansonBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Eileen E ParkesDepartment of Oncology, University of Oxford, Oxford, UK.ORCID 0000-0002-7855-3698

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIDA NIH HHS 75N95020D00005ORFDO NIH HHS 75N99020D00005Wellcome Trust
6 · The paper itself

Abstract

Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8

Indexed as

cancer immunityendoplasmic reticulumT cellTMEM33Tpex

Identifiers

PMID41509280
PMCPMC12776282

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.